重组人生长激素在体外对人直肠癌细胞株HR8348增殖的影响

目的　探讨重组人生长激素 (rhGH )在体外对人直肠癌细胞增殖的影响。方法　实验分为对照组、rhGH组、奥沙利铂 (L OHP)组和rhGH +L OHP组 4组 ,利用体外细胞培养、MTT比色技术及流式细胞仪等方法 ,测定不同浓度的rhGH对人直肠癌细胞株HR83 48细胞倍增时间、细胞抑制率、细胞周期、增殖指数 (PI)和DNA抑制率的影响。结果　rhGH在体外不促进HR83 48细胞的分裂增殖 ,rhGH组与对照组比较 ,以及rhGH +L OHP组与L OHP组比较 ,其差异均无统计学意义 (P>0 .0 5 ) ;rhGH +L OHP组与对照组比较及rhGH +L OHP组与对应的rhGH组配对比较 ,细胞倍增时间明显延长 ,细胞抑制率增加 ,阻滞于G0 ～G1期的细胞数增加 ,S期和G2 ～M期细胞明显减少 ,PI明显降低 ,DNA抑制率显著升高 (P<0 .0 1,S期P<0 .0 5 )。结论　rhGH在体外不促进直肠癌细胞的分裂增殖。     

过氧化氢对不同时相HepG2细胞氧化作用的研究

背景与目的:研究过氧化氢(H2O2)对不同时相HepG2细胞作用的选择性,以进一步探讨H2O2:诱导肿瘤细胞凋亡的机制.材料与方法:以胸腺嘧啶核苷(TdR)阻断法获得不同细胞周期时相的同步化细胞,分别加入800 μmol/L的H2O2作用3 h,并检测各组细胞的丙二醛(MDA)含量、黄嘌呤氧化酶(XOD)和5'核苷酸酶(5'NT)的活性及抗羟自由基(抗·OH)和抗超氧阴离子自由基(抗O2)的活性.结果:经H2O2处理的各组MDA含量和XOD、抗·OH、抗O2活性显著高于对照组,其差异均具有统计学意义(P均＜0.01),5'NT活性低于对照组(P＜0.01).与未同步化组比较,同步化于S期和G2/M期的细胞MDA含量和XOD、5'NT、抗·OH和抗O2活性显著升高,其差异均具有统计学意义(P均＜0.01),而同步化于G1期的细胞MDA含量、XOD、5'NT和抗O2-活性显著降低,差异均具有统计学意义(P均＜0.01).结论:H2O2作用同步化HepG2细胞后,代谢产生自由基的酶活性,脂质过氧化产物含量以及抗氧化水平均表现出细胞周期特异性,这可能是过氧化氢对不同时相HepG2细胞损伤作用不同的原因.     

Deregulation of cell proliferation by polycyclic aromatic hydrocarbons in human breast carcinoma MCF-7 cells reflects both genotoxic and nongenotoxic events.

Polycyclic aromatic hydrocarbons (PAHs), such as benzo[a]pyrene (BaP), are carcinogens suggested to be involved in development of human cancer. Several recent studies have reported that PAHs can activate estrogen receptors (ER), either directly or indirectly by producing estrogenic metabolites. We hypothesized that the activation of ER by PAHs or their metabolites could induce cell proliferation in estrogen-sensitive cells. In the present study, we found that two PAHs, benz[a]anthracene (BaA) and BaP, can stimulate proliferation of human breast carcinoma MCF-7 cells at concentrations 100 nM and higher. This effect was ER-dependent, because it was blocked by the pure antiestrogen ICI 182,780. Although both PAHs partially inhibited S-phase entry and DNA synthesis induced by 17beta-estradiol, they stimulated S-phase entry when applied to MCF-7 cells synchronized by serum deprivation. This was in contrast with model antiestrogenic aryl hydrocarbon receptor ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin, which fully suppressed S-phase entry. BaP, which is a strong mutagen, was found to induce p53 tumor suppressor expression, a partial S-phase arrest and at higher concentrations also cell death. Pifithrin-alpha, a synthetic inhibitor of p53 activity, abolished both S-phase arrest and apoptosis induced by genotoxic PAHs, and it potentiated the proliferative effect of BaP. Thus, both genotoxic and nongenotoxic events seem to interact in the effects of BaP on cell proliferation. Taken together, our data indicate that both BaA and BaP can stimulate cell proliferation through activation of ER. The proliferative effects of these carcinogenic compounds might contribute to tumor promotion in estrogen-sensitive tissues.     

血小板衍生性生长因子对低氧培养内皮细胞增殖的影响

目的　观察低氧条件下血小板衍生性生长因子 (PDGF)对于培养人脐静脉内皮细胞 (HUVEC)增殖的影响。方法　流式细胞仪分析细胞周期各时相分布 ,氚 -亮氨酸 (3 H -Leu)掺入实验评价蛋白质合成 ,免疫组织化学方法检测增殖细胞核抗原 (PCNA)水平。结果　低氧可显著减少S期及G2 /M期细胞数 ,使停留于G0 /G1 期HUVEC细胞数增加 ,降低HUVEC3 H -Leu的掺入量及PCHA水平。低浓度的PDGF(5ng/ml)对低氧条件培养的HUVEC细胞周期时相分布、3 H -Leu的掺入量及PCNA水平影响不明显 ;高浓度PDGF(1 0ng、2 0ng)加速HUVEC由G1 期S期的转换 ,显著增加低氧培养HUVEC3 H -Leu掺入量 ,PCNA水平 ,此作用呈剂量依赖性。结论　PDGF能够拮抗低氧所致的培养HUVEC增生能力的下降 ,但低浓度PDGF(5ng/ml)作用不显著 ,剂量越大 ,拮抗作用愈显著。     

Expression of pS2, c-erbB-2, and cathepsin D during the menstrual cycle in human breast cancers

Background: Many studies have addressed the effect of the timing of surgery for breast cancer relative to menstrual cycle phase, with conflicting results. Explanations for the possibility that survival could be altered by the appropriate timing of breast cancer surgery in humans remain speculative. Methods: We examined the expression of three estrogen related proteins (c-erbB-2, cathepsin D, pS2) in the breast tumors from 69 premenopausal women sampled in different phases of the menstrual cycle. Data on S-phase fraction and hormone receptor expression were also analyzed. Immunohistochemical assays were used to measure the proteins of interest. S-phase fraction was determined by flow cytometry. Analyses were performed based on fraction of cells staining positive for the protein, density of stain, and a histoscore that combined both fraction of positive cells and density. Results: We found no differences in c-erbB-2, cathepsin D, hormone receptor, or S-phase levels in tumors sampled in the follicular versus luteal phase, or perimenstrual versus periovulatory phase. The exception was pS2, which was expressed at greater levels during the luteal than during the follicular phase of the cycle (p<0.01); but there was no difference in pS2 expression when the patients were classified as periovulatory versus perimenstrual. Conclusions: Our findings do not support a variation in c-erbB-2, cathepsin D, S-phase fraction, or receptor expression as an explanation for the differences in breast cancer prognosis when surgery is timed by menstrual cycle phase. The finding that pS2 (an indicator of hormone sensitivity, and possibly better prognosis) is expressed at higher levels in tumor samples during the luteal phase suggests that the biologic profile of breast tumors may vary with the menstrual cycle and that these variations deserve further study.     

Relation Between Cycle Length, Volume, and Pressure in Type I Atrial Flutter

Assuming that type I atrial flutter is a macroreentrant circuit, its cycle length should vary with the atrial dimensions. In order to test this hypothesis, flutter cycle length was measured while inducing atrial volume and pressure changes by postural and pharmacological means in seven patients undergoing a therapeutic programmed stimulation for type 1 atrial flutter conversion. Right atrial volume was estimated from B-mode echocardiography data. Basal values were compared with those obtained during inspiration, expiration, Valsalva maneuver, negative tilt (head down), and positive tilt (head up) with 0.8–1.6 mg p.o. nitroglycerin. The right atrial size increased slightly from 17.8 to 18.3 cm² (P = 0.04) during the pressure load induced by negative tilt (+ 3 mmHg), with a corresponding lengthening of the flutter cycle length from 228 to 233 msec (P = 0.02). Similarly, pressure unloading of -2 mmHg by positive tilting and nitrates was accompanied by a decrease in right atrial size to 16.6 cm² (P = 0.04), with a corresponding decrease in cycle length from 228 to 219 msec (P = 0.03). Respiratory maneuver yielded similar results with an inspiratory cycle lengthening, expiratory shortening, and further shortening during Valsalva maneuver. These experiments demonstrate a direct relation between cycle length and atrial volume in human type I atrial flutter. They underline the importance of the right heart preload and atrial size for the electrophysiological characteristics of type I atrial flutter. Beside its fundamental interest, this finding is important for the understanding of the mechanism of maintenance and therapeutic responses of this common arrhythmia.     

医用氧舱检验与安全

本文介绍了医用氧舱的检验，医用氧舱的检验包括舱体、供排气、氧系统、电气系统等“硬件”设备的检验和设计、安装与使用管理的“软件”方面的检验。同时，针对检验过程中发现的影响医用氧舱安全使用的常见问题，本文进行了详细的讨论。     

Cdh1小干扰RNA载体的构建及鉴定

目的:构建Cdh1小干扰RNA载体,并将其转染至Hela细胞进行鉴定.方法:根据pENTRTM/H1/TO中间载体要求,设计Cdh1小干扰RNA载体的干扰序列及无干扰作用的对照序列,合成相应的DNA单链,退火后连接到pENTRTM/H1/TO线性载体,形成完整载体,进行测序鉴定.分别将测序鉴定成功的Cdh1小干扰RNA载体及对照载体采用脂质体法转染Hela细胞,转染后48 h提取细胞总RNA及细胞总蛋白,采用实时定量PCR和Western Blot检测Cdh1的表达.结果:经测序鉴定成功构建Cdh1小干扰RNA载体和对照载体,分别命名为pENTR/shCdh1和pENTR/shcontrol.与未转染及转染pENTR/shcontrol的Hela细胞相比,转染pENTR/shCdh1的Hela细胞Cdh1表达降低(P《0.05).结论:成功构建Cdh1小干扰RNA载体,并能下调Hela细胞Cdh1的表达.     

人埃立克体的传播途径及其遗传基础

本文从媒介、宿主、传播途径及其遗传学基础对埃立克体传播循环中获得的最新进展进行综述性回顾,为人埃立克体病的预防提供技术支持和基础资料。     

Clinical outcomes of two different endometrial preparation methods for cryopreserved-thawed embryo transfer in patients with a normal menstrual cycle

Aim:  To compare the clinical outcomes of cryopreserved-thawed embryo transfer among patients with a normal menstrual cycle who had natural or hormone-replacement cycles.
Methods:  From January 2004 to June 2006, cryopreserved embryos following conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) were thawed and transferred in a total of 720 natural cycles and 136 hormone-replacement cycles.
Results:  Cryopreserved-thawed embryo transfer in patients who had a natural or hormone-replacement cycle resulted in clinical pregnancy in 43.1% and 40.4%, respectively; a rate of miscarriage of 14.5% and 23.6%, respectively; and a rate of ongoing pregnancy and delivery of 36.5% and 30.9%, respectively. None of these differences were statistically significant.
Conclusions:   Patients with a normal menstrual cycle who have natural or hormone-replacement cycles can be expected to have comparable clinical outcomes with cryopreserved-thawed embryo transfer. (Reprod Med Biol 2007; 6 : 53–57)